Haisco Pharmaceutical Group Co., Ltd.

Haisco Pharmaceutical Group Co., Ltd. faced a challenging trading session, with a notable decline in stock performance. Despite recent pressures, the company has demonstrated strong long-term growth, with significant increases in year-to-date and decade-long performance. Haisco maintains a solid operational foundation and a substantial market capitalization.

Haisco Pharmaceutical Group Co., Ltd. saw a notable stock decline today, contrasting with the broader market's performance. Despite this, the company has demonstrated strong long-term growth, with significant increases over the past month and three years. Financial metrics indicate robust operational performance and a commitment to shareholder value.

Haisco Pharmaceutical Group Co., Ltd. has seen remarkable stock performance, with a notable increase on July 1, 2026. The company reported a substantial net profit rise and record operating cash flow, reinforcing its strong position in the pharmaceuticals sector and consistently outperforming the broader market over recent years.

Haisco Pharmaceutical Group Co., Ltd. has shown notable stock performance, reaching an intraday high and achieving substantial gains over various time frames. The company reported impressive financial metrics, including significant net profit growth and strong operating cash flow, reinforcing its status in the pharmaceuticals and biotechnology sector.

Haisco Pharmaceutical Group Co., Ltd. has shown remarkable stock performance, with a 24.03% increase over the past week and a 44.11% rise over the past year. The company boasts strong financial metrics, including high operating cash flow and a significant decline in raw material costs, enhancing profitability.

Haisco Pharmaceutical Group Co., Ltd. has shown impressive stock performance, gaining 8.08% on June 23, 2026, amid a declining market. The company reported significant annual growth of 24.53% and a remarkable net profit increase of 1089.85% in March 2026, highlighting its strong position in the pharmaceuticals sector.

Haisco Pharmaceutical Group Co., Ltd. experienced notable stock activity, reaching an intraday high while the broader market declined. The company reported impressive net profit growth and strong operating cash flow, alongside a significant reduction in raw material costs, reinforcing its competitive position in the pharmaceuticals sector.

Haisco Pharmaceutical Group Co., Ltd. has recently experienced a change in evaluation, reflecting a complex analysis of its technical indicators and market position. While short-term trends show cautious optimism, the company faces challenges in long-term growth metrics, including modest profit growth and a relatively high price-to-book value.

Haisco Pharmaceutical Group Co., Ltd. has shown strong stock performance, gaining 7.46% on March 27, 2026, and outperforming the China Shanghai Composite over various timeframes. The company has achieved significant long-term growth, with a 134.64% increase over three years and a 238.07% rise over the past decade.

Haisco Pharmaceutical Group Co., Ltd. saw a significant stock decline on March 23, 2026, amid a challenging trading session. Despite recent fluctuations, the company has shown strong annual returns and impressive long-term growth, although it faces valuation challenges with a high price-to-earnings ratio and modest return on equity.

Haisco Pharmaceutical Group Co., Ltd. saw a significant intraday increase on March 17, 2026, contrasting with a decline in the broader market. The company has shown positive weekly and monthly trends, with impressive annual returns, though it faces challenges with a high price-to-earnings ratio and modest dividend yield.

Haisco Pharmaceutical Group Co., Ltd. has seen significant stock performance, rising 5.46% today and achieving an intraday high of CNY 49.18. Over the past year, the company has gained 41.65%, outperforming the broader market, while maintaining a strong long-term growth trajectory with substantial increases over three and five years.

Haisco Pharmaceutical Group Co., Ltd. has seen notable stock activity, achieving an intraday high and a weekly gain of over 10%. Despite a year-to-date decline, the company boasts a strong one-year performance and a market capitalization of CNY 25,698 million, with a price-to-earnings ratio of 141.00.

Haisco Pharmaceutical Group Co., Ltd. saw a significant stock increase today, contrasting with the modest rise of the China Shanghai Composite. Over the past year, Haisco has achieved a strong annual return, despite a year-to-date decline, and maintains a notable market capitalization within the Pharmaceuticals & Biotechnology sector.

Haisco Pharmaceutical Group Co., Ltd. faced a significant decline in stock performance, with a notable drop today and over the past week. Despite a challenging year-to-date performance, the company has shown substantial growth over three and five years. Key financial metrics reflect a high price-to-earnings ratio and modest dividend yield.

Haisco Pharmaceutical Group Co., Ltd. faced a decline in stock performance, with a notable drop today and a significant decrease over the past week. Year-to-date, the stock has decreased, contrasting with broader market gains. The company has a high price-to-earnings ratio and a modest dividend yield, indicating a complex financial landscape.